Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
Provided By GlobeNewswire
Last update: Jan 8, 2025
CORAL GABLES, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company and its licensor SERB S.A. (“SERB”) have entered into a Settlement Agreement (Agreement) with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals, Inc. (collectively Teva). This Agreement resolves the patent litigation brought by Catalyst and SERB in response to Teva’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of FIRDAPSE® (amifampridine) 10 mg tablets prior to expiration of the applicable patents.
Read more at globenewswire.com21.62
-0.43 (-1.95%)
Find more stocks in the Stock Screener
CPRX Latest News and Analysis
10 days ago - ChartmillWhy NASDAQ:CPRX qualifies as a high growth stock.A fundamental analysis of (NASDAQ:CPRX): Delving into CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s Growth Prospects.
11 days ago - ChartmillInvestors should take note of NASDAQ:CPRX, a growth stock that remains attractively priced.Based on Fundamental Analysis it can be said that NASDAQ:CPRX is a growth stock which is not overvalued.
12 days ago - ChartmillUnlocking the Growth Potential of NASDAQ:CPRX.A fundamental analysis of (NASDAQ:CPRX): Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock.
13 days ago - ChartmillExploring NASDAQ:CPRX's high growth characteristics.CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a candidate for high growth investors. Here's why. Full fundamental and technical analysis of (NASDAQ:CPRX).
16 days ago - ChartmillWhy NASDAQ:CPRX Is a Promising High-Growth Stock in the Midst of Consolidation.Based on a technical and fundamental analysis of NASDAQ:CPRX we can say: CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), a strong growth stock, setting up for a breakout.
18 days ago - ChartmillNASDAQ:CPRX: good value for what you're paying.Uncover the potential of CATALYST PHARMACEUTICALS INC, an undervalued stock. NASDAQ:CPRX maintains a strong financial position and offers an appealing valuation.
